Interleukin-6 Receptors (Interleukin 6 Receptor)

Cell surface receptors that are specific for INTERLEUKIN-6. They are present on T-LYMPHOCYTES, mitogen-activated B-LYMPHOCYTES, and peripheral MONOCYTES. The receptors are heterodimers of the INTERLEUKIN-6 RECEPTOR ALPHA SUBUNIT and the CYTOKINE RECEPTOR GP130.

Also Known As:

Networked: 613 relevant articles (26 outcomes, 70 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Rose-John, Stefan: 14 articles (10/2015 - 09/2003)
2.	Nishimoto, Norihiro: 13 articles (04/2014 - 12/2002)
3.	Kishimoto, Tadamitsu: 11 articles (04/2014 - 07/2003)
4.	Jones, Simon A: 8 articles (11/2014 - 09/2003)
5.	Mihara, Masahiko: 7 articles (01/2011 - 06/2004)
6.	Ohsugi, Yoshiyuki: 6 articles (08/2010 - 07/2005)
7.	Yoshizaki, Kazuyuki: 6 articles (06/2009 - 12/2002)
8.	Scheller, Jürgen: 5 articles (09/2014 - 09/2006)
9.	Anderson, Kenneth C: 5 articles (12/2012 - 06/2005)
10.	Ando, Yukio: 4 articles (11/2015 - 08/2009)

Related Diseases

1.	Rheumatoid Arthritis 09/01/2014 - "To evaluate safety and efficacy of weekly (qw) and every other week (q2w) dosing of sarilumab, a fully human anti-interleukin 6 receptor α (anti-IL-6Rα) monoclonal antibody, for moderate-to-severe rheumatoid arthritis (RA). " 07/01/2003 - "Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. " 02/01/2015 - "Chemerin and cardiovascular risk in rheumatoid arthritis after interleukin 6 receptor blockade." 09/01/2012 - "Both innate and adaptative immunity demonstrated their respective cornerstone position in rheumatoid arthritis, since targeted treatments has been efficiently developed against TNF-α, IL-6 receptor, IL-1β, CD20 B cells and T-cell/Dendritic cell interactions." 01/01/2012 - "Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis."
2.	Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis) 09/01/1998 - "A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis." 05/01/1994 - "By using a sandwich ELISA, soluble human IL-6 receptor (sIL-6 R) levels were measured in the sera of 20 healthy children and of 25 patients with systemic juvenile rheumatoid arthritis (JRA). " 01/01/2005 - "Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement." 04/01/2014 - "Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan." 03/01/2013 - "Currently, tocilizumab, which binds the IL-6 receptor, is licensed for treatment in active, moderate to severe disease in RA and systemic juvenile idiopathic arthritis (JIA). "
3.	Giant Lymph Node Hyperplasia (Castleman's Disease) 11/01/2000 - "In this review, the new therapeutic strategy for Castleman's disease and RA using humanized antibody to human IL6 receptor, MRA, is discussed." 01/01/2015 - "Discovery of Innovative Therapies for Rare Immune-Mediated Inflammatory Diseases via Off-Label Prescription of Biologics: The Case of IL-6 Receptor Blockade in Castleman's Disease." 01/01/2014 - "Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases." 01/01/2013 - "We hypothesized that interleukin-6/interleukin-6 receptor/gp130 polymorphisms contribute to increased interleukin-6 and/or other components of the interleukin-6 signaling pathway in HIV-negative Castleman Disease patients. " 12/01/2005 - "[Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease]."
4.	Vasculitis (Vasculitides) 01/01/2012 - "Preliminary data also suggest efficacy of the IL-6 receptor inhibitor tocilizumab in patients with large-vessel vasculitis. " 08/01/2013 - "We performed a systematic literature search (PubMed until July 2012) using the terms "tocilizumab," "anti-IL-6-receptor," "polymyalgia rheumatica," "giant cell arteritis", and "large-vessel vasculitis" to identify published reports of patients with PMR treated with TCZ. " 01/01/2002 - "The plasma levels of TNFalpha, its soluble receptor p75 (sTNF-RII), IL-6, and the soluble IL-6 receptor (sIL-6R) were measured using ELISA in 17 patients with ANCA-positive renal vasculitis (12 active - ANCA-A, 7 in remission ANCA-R), 9 patients with active lupus nephritis (LN), and 5 healthy subjects. " 05/04/1998 - "Plasma levels of TNF alpha, its soluble receptor p75 (sTNF-RII), IL-6 and soluble IL-6 receptor (sIL-6R) were measured using ELISA in 17 pts with ANCA-positive renal vasculitis (12 active-ANCA-A, 7 in remission ANCA-R), 9 pts with active lupus nephritis (LN) and 5 healthy subjects. " 01/01/2013 - "Encouraging preliminary results have been obtained with the IL-6 receptor (IL-6R) antagonist tocilizumab for the treatment of large-vessel vasculitides, including both giant cell arteritis and Takayasu arteritis, and the aortitis of Cogan syndrome and relapsing polychondritis. "
5.	Neoplasms (Cancer) 09/01/2015 - "Accordingly, targeted inhibition of the IL6 receptor and its downstream effectors JAK1 and STAT3 dramatically reduced tumor cell growth. " 02/15/2014 - "Treating mice with soluble IL-6 receptor fusion protein or silencing STAT3 in tumor cells significantly reduced prostate tumor growth and CSCs. " 01/01/2014 - "To interfere with IL-6-dependent diseases, targeting IL-6 receptor (IL-6R)-presenting tumor cells using aptamers might be a valuable strategy to broaden established IL-6- or IL-6R-directed treatment regimens. " 07/01/2012 - "Interleukin 6 receptor was expressed across multiple cancer cell lines. " 05/01/2012 - "The interleukin 6 receptor is a direct transcriptional target of E2F3 in prostate tumor derived cells."

Related Drugs and Biologics

1.	tocilizumab
2.	Interleukin-6 (Interleukin 6)
3.	Antineutrophil Cytoplasmic Antibodies (ANCA)
4.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
5.	A 7 (A-7)
6.	Cytokines
7.	Antibodies
8.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
9.	Interferons
10.	Methotrexate (Mexate)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Transplantation (Transplant Recipients)
3.	Immunomodulation
4.	Peritoneal Dialysis
5.	Arthroplasty